Circulation: Cardiovascular Interventions

MARCH 4, 2024

BACKGROUND:Transcatheter edge-to-edge mitral valve (MV) repair (TEER) is an effective treatment for patients with primary mitral regurgitation at prohibitive risk for surgical MV repair (MVr). Heart failure readmission at 1 year was 9.4% Circulation: Cardiovascular Interventions, Ahead of Print.

Bicuspid/Mitral 72

Bicuspid/Mitral Hospital Outcomes Heart Failure 72

Frontiers in Cardiovascular Medicine

JANUARY 25, 2024

The implantation of left ventricular assist devices (LVADs) has been increasing, with good long-term results, in parallel with a growing population with advanced heart failure (HF). However, in some European countries, LVADs are still underused, with one of the main issues being the patient's late referral.

Bicuspid/Mitral 69

Bicuspid/Mitral Heart Failure Heart Transplant Transplant 69

Medical Xpress - Cardiology

SEPTEMBER 3, 2024

Mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalizations with improved health status in patients with HF and moderate to severe functional mitral regurgitation (FMR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Bicuspid/Mitral 52

Bicuspid/Mitral Heart Failure Hospital Research 52

DAIC

SEPTEMBER 4, 2024

1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid aortic valve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications. tim.hodson Wed, 09/04/2024 - 15:53 Sept.

Aortic valve 52

Aortic valve Bicuspid/Mitral Aortic Research 52

HCPLive

AUGUST 31, 2024

RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.

Quality of Life 65

Quality of Life Bicuspid/Mitral Heart Failure Hospital 65

DAIC

FEBRUARY 21, 2024

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. Other symptoms include swelling in the abdomen, legs or neck veins.

Heart Failure 105

Heart Failure Open-Heart Surgery Tricuspid Heart Disease 105

Heart BMJ

AUGUST 14, 2024

Severe secondary mitral regurgitation carries a poor prognosis with one in five patients dying within 12 months of diagnosis. Optimal guideline-directed medical therapy is the mainstay therapy and has been shown to reduce the severity of mitral regurgitation in 40–45% of patients. to reduce heart failure hospitalisation and 5.9

Bicuspid/Mitral 59

Bicuspid/Mitral Atrial Fibrillation Heart Failure Outcomes 59

Med Page Today

AUGUST 31, 2024

(MedPage Today) -- LONDON -- Despite another positive trial, controversy rages on over transcatheter edge-to-edge repair (TEER or M-TEER) in people with symptomatic heart failure (HF) and functional mitral regurgitation (MR). All three primary.

Bicuspid/Mitral 59

Bicuspid/Mitral Heart Failure 59

Journal of the American Heart Association

DECEMBER 24, 2024

Journal of the American Heart Association, Ahead of Print. However, the magnitude to which mTEER increases the number of days a patient spends at home (DAH) in the first few years after treatment, a patientcentered end point not captured routinely in clinical trials, has not been evaluated.

Bicuspid/Mitral 45

Bicuspid/Mitral Heart Failure Medicare Inpatient 45

Open Heart

DECEMBER 7, 2023

Objectives Prognostic impact of lung ultrasound-derived B-lines (LUS-BL) in heart failure with mildly reduced left ventricular ejection fraction (HFmrEF) patients remains elusive. to 2.94), increased ratio of early transmitral flow velocity to early mitral annular velocity (>24, HR=1.79, 95% CI 1.11

Ultrasound 98

Ultrasound Heart Failure Risk Factors Bicuspid/Mitral 98

American College of Cardiology

DECEMBER 10, 2024

The RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: Second Trial in Patients With Clinically Significant Functional Mitral Regurgitation) trial was an international, open-label, multicenter, randomized controlled trial designed to provide additional information regarding the safety and effectiveness of M-TEER in this (..)

Bicuspid/Mitral 45

Bicuspid/Mitral Heart Failure Article 45

American College of Cardiology

AUGUST 31, 2024

The goal of the RESHAPE-HF2 trial was to assess the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 43

Bicuspid/Mitral Heart Failure Article 43

The American Journal of Cardiology

DECEMBER 13, 2023

Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): Esther Munerato Figueira da Silva, Raquel Martins Loureiro, Renan Shida Marinho, Júlia Marioti, Samuel Sá, Gabriela Pereira Gil Castilho, Guilherme Casale, Audrey Borghi Silva, Carlos Henrique de Freitas Lima, Meliza Goi Roscani

Heart Failure 98

Heart Failure Bicuspid/Mitral Exercise 98

CardiacWire

JULY 28, 2024

Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.

Heart Failure 59

Heart Failure Aortic TAVR Critical Care 59

DAIC

FEBRUARY 20, 2024

The Intrepid TMVR is a heart valve that is designed to help alleviate mitral regurgitation so that blood can flow through the heart in the intended direction,” said Matthew Saybolt , M.D., FACC, principal site investigator and medical director, Structural Heart Disease Program, Jersey Shore University Medical Center.

Heart Valves 116

Heart Valves Bicuspid/Mitral Academic Chest Pain 116

American College of Cardiology

AUGUST 31, 2024

The goal of the MATTERHORN trial was to evaluate mitral transcatheter edge-to-edge repair (M-TEER) compared with surgical mitral valve repair among patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 43

Bicuspid/Mitral Heart Failure Article 43

American College of Cardiology

NOVEMBER 5, 2024

The goal of the COAPT trial was to assess the safety and efficacy of transcatheter mitral leaflet approximation using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).

Bicuspid/Mitral 40

Bicuspid/Mitral Heart Failure Outcomes Article 40

Nature Reviews - Cardiology

SEPTEMBER 18, 2024

Nature Reviews Cardiology, Published online: 19 September 2024; doi:10.1038/s41569-024-01089-9 In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an (..)

Bicuspid/Mitral 52

Bicuspid/Mitral Heart Failure Hospital Stroke 52

European Journal of Heart Failure

APRIL 17, 2024

HFpEF, heart failure with preserved ejection fraction; MR, mitral valve regurgitation. Abstract Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Bicuspid/Mitral Heart Failure Pulmonary 40

European Journal of Heart Failure

FEBRUARY 26, 2025

Proposed approach for clinical management and therapeutic optimization in patients with heart failure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.

Blood Pressure 58

Blood Pressure Heart Failure Aortic valve TAVR 58

DAIC

MARCH 4, 2025

If untreated, it can lead to severe complications, including heart failure and death. Key symptoms of aortic stenosis include: Chest pain Shortness of breath Dizziness or fainting Fatigue Rapid or irregular heartbeat Gender Disparities Studies have shown that women and men experience heart valve disease differently.

Heart Valves 52

Heart Valves Aortic valve Aortic Stenosis 52

CardiacWire

JUNE 21, 2024

Columbia and Cornell researchers developed an echo AI model that could improve the difficult task of mitral regurgitation diagnosis, and might even represent an AI-driven step towards enhancing all valvular regurgitation assessments. The post New Echo AI Model Could Streamline Mitral Regurgitation Diagnosis appeared first on Cardiac Wire.

Bicuspid/Mitral 59

Bicuspid/Mitral Research Academic Heart Failure 59

DAIC

JUNE 11, 2024

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

Tricuspid 52

Tricuspid Bicuspid/Mitral Heart Valves Innovation 52

Frontiers in Cardiovascular Medicine

OCTOBER 7, 2024

BackgroundEmerging evidence indicates a significant link between various immune cell types and the development of heart valve disorders. Mitral valve prolapse (MVP) is a common condition that can lead to heart failure, arrhythmias, and even sudden death. Currently, the role of immune cells in MVP is not well understood.

Bicuspid/Mitral 59

Bicuspid/Mitral Heart Valves Heart Failure Arrhythmia 59

American College of Cardiology

DECEMBER 16, 2024

Transcatheter edge-to-edge repair (TEER) and mitral valve (MV) surgery (both replacement and repair) are two approaches for managing patients with heart failure (HF) and secondary mitral regurgitation (MR).

Bicuspid/Mitral 41

Bicuspid/Mitral Heart Failure Article 41

Heart BMJ

DECEMBER 13, 2024

Secondary mitral regurgitation (SMR) is a complex and evolving challenge in the landscape of heart failure (HF) management. Or should we adopt an integrated approach, incorporating early mitral valve intervention, especially for patients with persistent symptoms despite.

Pharmacology 52

Pharmacology Bicuspid/Mitral Heart Failure Outcomes 52

European Journal of Heart Failure

DECEMBER 11, 2024

Abstract Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock.

Cardiogenic Shock 68

Cardiogenic Shock Heart Disease Heart Failure Bicuspid/Mitral 68

DAIC

JANUARY 8, 2024

milla1cf Mon, 01/08/2024 - 14:35 January 8, 2024 — University Hospitals (UH) Harrington Heart & Vascular Institute recently became the first center in the world to implant Medtronic’s Penditure Left Atrial Appendage (LAA) Exclusion System through a minimally invasive approach during a mitral valve repair procedure.

Bicuspid/Mitral 124

Bicuspid/Mitral Atrial Fibrillation Anatomy Coronary Artery Disease 124

The New England Journal of Medicine

NOVEMBER 13, 2024

Functional mitral regurgitation is a disease of the left heart as opposed to the valve leaflets themselves. Two thirds of patients with heart failure have moderate or severe functional mitral regurgitation.1

Bicuspid/Mitral 40

Bicuspid/Mitral Heart Failure 40

DAIC

FEBRUARY 15, 2024

The device is being developed as a first-in-class implantable sensor to provide daily adjunctive objective cardiac parameter measurements enabling patients and clinicians to better manage their congestive heart failure symptoms with current medication management tools. heart failure market is projected to be $70B annually by 2030.

Heart Failure 105

Heart Failure Technology Bicuspid/Mitral Research 105

Frontiers in Cardiovascular Medicine

JANUARY 14, 2024

Background Echocardiography-guided percutaneous intramyocardial alginate-hydrogel implantation (PIMAHI) is a novel treatment approach for heart failure (HF). We validated PIMAHI safety and efficacy in canine HF models. Compared with controls at 6-month, PIMAHI group significantly increased LVFW thickness (8.5 ± 0.3 vs. 6.8 ± 0.2 mm,

Heart Failure 64

Heart Failure Outcomes Bicuspid/Mitral Arrhythmia 64

DAIC

JUNE 5, 2024

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.

Critical Care 105

Critical Care Tricuspid Innovation Bicuspid/Mitral 105

DAIC

FEBRUARY 15, 2024

Advances in Transcatheter Tricuspid Valve Technologies VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.

Tricuspid 102

Tricuspid Heart Valves Quality of Life Bicuspid/Mitral 102

HeartRhythm

APRIL 30, 2024

The development of AF is an indication for surgical mitral valve replacement in patients with severe mitral regurgitation. However, some patients only experience arrhythmia episodes without other indications, such as decreased ejection fraction or heart failure.

Bicuspid/Mitral 40

Bicuspid/Mitral Atrial Fibrillation Heart Failure Ablation 40

Circulation

NOVEMBER 11, 2024

All-cause hospitalization (HR: 2.31, 95%CI: 2.04 – 2.62, p&lt;0.001), heart failure hospitalization (HR: 2.22, 95%CI: 1.92 – 2.55, p&lt;0.001), acute myocardial infarction (HR: 2.06, 95%CI: 1.79 – 2.35, p&lt;0.001), unstable angina (HR: 2.28, 95%CI: 1.72-3.04, vs non-MAC (58.2 + 12.6).

Heart Failure 40

Heart Failure Preserved Ejection Fraction Bicuspid/Mitral Outcomes 40

Dr. S. Venkatesan MD

OCTOBER 11, 2024

In the process, improving the ejection fraction and possibly reducing mitral regurgitation. However, advanced heart failure therapy never means it can be achieved only by state-of-the-art technology. Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure. 2021 May 21;23(5):740-747. Reference 1.

Heart Failure 59

Heart Failure Anatomy Ultrasound Technology 59

Circulation: Cardiovascular Interventions

JANUARY 18, 2024

BACKGROUND:Limited data exist regarding the impact of mitral annular calcification (MAC) on outcomes of transcatheter edge-to-edge repair for mitral regurgitation (MR).METHODS:We Circulation: Cardiovascular Interventions, Ahead of Print. with functional MR) who underwent an isolated, first-time intervention. versus 9.6%;P=0.016;

Bicuspid/Mitral 40

Bicuspid/Mitral Outcomes Heart Failure Echocardiogram 40